Active substance Ramucirumab
Domain Oncology and Hematology
Reason of inclusion Indication extension
Main indication Bladder cancer
Extended indication Advanced urothelial cancer, second line.


Proprietary name Cyramza
Manufacturer Eli Lilly
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional comments Anti-VEGF receptor 2 antibody.


Registration route Centralised (EMA)
Orphan drug No
Registration phase No registration expected
Additional comments Update fabrikant: Hiervoor wordt geen registratie aangevraagd

Therapeutic value

Current treatment options Sinds kort immunotherapie
Therapeutic value Potential equal value
Duration of treatment Median 12 week / weeks
Frequency of administration 2 times a month
Dosage per administration 10 mg/kg
References Petrylak et al. Lancet. 2017 Nov 18;390(10109):2266-2277
Additional comments Behandelschema: 12 weken/4 toedieningen; 1 maal per 3 weken.

Expected patient volume per year

Patient volume


Market share is generally not included unless otherwise stated.

Additional comments De verwachting is dat met de introductie van immunotherapie deze behandeling niet tot vrijwel niet zal worden voorgeschreven.

Expected cost per patient per year

Cost 15,000.00 - 20,000.00
References Medicijnkosten.nl
Additional comments Meerkosten. Bij aantal toedieningen van vier; 75 kg gewicht; 10 mg/kg; betekent zes ampullen 10 mg/l van 50 ml: €17.171,94.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

Off label use No

Indication extension

Indication extension No

Other information

There is currently no futher information available.